Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 1
2015 4
2016 1
2017 1
2020 1
2021 2
2022 3
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean atassi m[au] (382 results)?
Secukinumab demonstrated sustained retention, effectiveness and safety in a real-world setting in patients with moderate-to-severe plaque psoriasis: long-term results from an interim analysis of the SERENA study.
Augustin M, Sator PG, von Kiedrowski R, Conrad C, Rigopoulos D, Romanelli M, Ghislain PD, Torres T, Ioannides D, Aassi M, Schulz B, Jagiello P; SERENA study group. Augustin M, et al. Among authors: aassi m. J Eur Acad Dermatol Venereol. 2022 Oct;36(10):1796-1804. doi: 10.1111/jdv.18329. Epub 2022 Jul 4. J Eur Acad Dermatol Venereol. 2022. PMID: 35696305
Effect of Secukinumab and Tumor Necrosis Factor Inhibitors on Humoral Response to BNT162b2 mRNA Vaccine in Patients With Spondyloarthritis Compared to Immunocompetent Controls.
Eviatar T, Furer V, Polachek A, Zisman D, Peleg H, Elalouf O, Levartovsky D, Kaufman I, Broyde A, Haddad A, Feld J, Aassi M, Quebe-Fehling E, Alarcon I, Pel S, Paran D, Elkayam O. Eviatar T, et al. Among authors: aassi m. J Rheumatol. 2023 Nov 1:jrheum.2023-0357. doi: 10.3899/jrheum.2023-0357. Online ahead of print. J Rheumatol. 2023. PMID: 37914221 Free article.
First-in-human study demonstrating the safety and clinical efficacy of novel anti-IL-17A monoclonal antibody CJM112 in moderate to severe plaque psoriasis.
Kaul M, Jarvis P, Rozenberg I, Kolbinger F, Di Padova F, Calonder C, Espie P, Rondeau JM, Cebe R, Huber T, Mussmann R, Aassi M, Sligh TS. Kaul M, et al. Among authors: aassi m. J Eur Acad Dermatol Venereol. 2021 May;35(5):1143-1151. doi: 10.1111/jdv.17071. Epub 2021 Jan 5. J Eur Acad Dermatol Venereol. 2021. PMID: 33617042 Free PMC article. Clinical Trial.
Twelve-week secukinumab treatment is consistently efficacious for moderate-to-severe psoriasis regardless of prior biologic and non-biologic systemic treatment: Post hoc analysis of six randomised trials.
Hampton P, Halliday A, Aassi M, Subramanian S, Jain M, Griffiths CEM. Hampton P, et al. Among authors: aassi m. J Eur Acad Dermatol Venereol. 2021 Apr;35(4):928-937. doi: 10.1111/jdv.16982. Epub 2021 Feb 9. J Eur Acad Dermatol Venereol. 2021. PMID: 33030755 Free PMC article.
Secukinumab Use in Patients with Moderate to Severe Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis in Real-World Setting in Europe: Baseline Data from SERENA Study.
Kiltz U, Sfikakis PP, Gaffney K, Sator PG, von Kiedrowski R, Bounas A, Gullick N, Conrad C, Rigopoulos D, Lespessailles E, Romanelli M, Ghislain PD, Brandt-Jürgens J, Rashkov R, Aassi M, Orsenigo R, Perella C, Pournara E, Gathmann S, Jagiello P, Veit J, Augustin M. Kiltz U, et al. Among authors: aassi m. Adv Ther. 2020 Jun;37(6):2865-2883. doi: 10.1007/s12325-020-01352-8. Epub 2020 May 6. Adv Ther. 2020. PMID: 32378070 Free PMC article.
13 results